Technology Transfer Offices and the Commercialisation of University Research in the United States

1986 ◽  
Vol 2 (2) ◽  
pp. 299-316
Author(s):  
Martha Caldwell Harris

El intercambio de la tecnología ha llegado a ser un punto de controversia en la relaciones estadounidenses-mexicanas. En un clima de una política incierta, el rango y la efectividad de la transferencia de la tecnología continuarán a ser limitados a menos que se tomen pasos significativos para establecer un nuevo curso de dirección.


1988 ◽  
Vol 24 (1-4) ◽  
pp. 537-539 ◽  
Author(s):  
H.M. Mardis ◽  
R.J. Guimond ◽  
E. Fisher

Abstract The United States Environmental Protection Agency's (USEPA) House Evaluation Program (HEP) is an on-going programme designed to transfer research findings on radon diagnostic and mitigation technologies to the general public. The HEP accomplishes this technology transfer by providing guidance and hands-on training to States, homeowners, and local contractors while conducting radon diagnostics and mitigation design planning in houses. An overview of the HEP is given and the programme's accomplishments and findings to date are discussed.


Author(s):  
V.A. Shumaev ◽  
N.A. Divueva ◽  
N.A. Lukasheva

The article summarizes the experience of the United States, Germany and Asian countries in creating and organizing the development and functioning of innovative systems, technology transfer, building a high-tech industry, which is advisable to use in Russia.


2007 ◽  
Vol 21 (2) ◽  
pp. 169-174
Author(s):  
Mark B. Wilson ◽  
Daniel Alge

Many jurisdictions, including the European Patent Office (EPO), have opposition proceedings in which an interested third party can challenge the validity of the claims of an issued patent. The United States Congress is considering legislation that would introduce opposition proceedings in the USA. This paper reviews the existing EPO and proposed US opposition procedures and provides practical suggestions for dealing with oppositions.


2012 ◽  
Vol 18 (2) ◽  
Author(s):  
Wesley Daniel Blakeslee

Abstract The biopharmaceutical industry has been undergoing change for a number of years and that change is accelerating.  Larger pharmaceutical companies are acquiring smaller ones, companies are merging, laboratories are being closed, and the number of scientists performing research in the pharmaceutical industry is declining.  Overall, commercial industry, including the biotechnology industry, is becoming more interested in the benefits of collaboration with research institutions.Universities are also changing their view of relationships with industry.  Shrinking federal budgets are causing universities to look at other sources of revenue, including collaborations with industry.  Federal and state governments are also looking closely at the benefits of sponsoring university research, and in particular are seeking to accelerate commercialization of university discoveries not only to obtain the benefit of invested research dollars, but also for economic development and job growth.  Universities, and in particular university technology transfer offices, must understand these changes and adapt to them. This paper discusses the university/industry relationships, and the particular issues important to universities which shape that interface. 


Sign in / Sign up

Export Citation Format

Share Document